Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.
In the 25 years since its first description the p53 protein has been shown to play a key role in both tumour suppression and aging. New discoveries about the function and control of p53 continue to emerge every month and attempts to exploit the system to develop better therapeutics and diagnostics are beginning to be successful in the clinic.
Lane
David
D
Department of Surgery and Molecular Oncology, Ninewells Hospital, University of Dundee, Dundee DD1 9SY, UK. d.p.lane@dundee.ac.uk
D000256:Adenoviridae; D000818:Animals; D019941:Cyclin-Dependent Kinase Inhibitor p16; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D025803:Tumor Suppressor Protein p14ARF / Q000235:genetics / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D014765:Viral Vaccines / Q000235:genetics
C417743:Cdkn2a protein, mouse; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D025803:Tumor Suppressor Protein p14ARF; D016159:Tumor Suppressor Protein p53; D014765:Viral Vaccines; C464532:dl1520; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2